BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Kristian Aarslev, Anders Dige, Stinne R. Greisen, Martin Kreutzfeldt, Niels Jessen, Hendrik Vilstrup, Bent Deleuran, Henning Grønbæk. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitisScandinavian Journal of Gastroenterology 2017; 52(1): 93 doi: 10.1080/00365521.2016.1233576
2
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Laura Gragnani, Angela Buonadonna, Emanuela Vaccher, Anna Linda Zignego, Agostino Steffan, Franco M. Buonaguro. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular CarcinomaFrontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.00475
3
Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro. Immunotherapy of Hepatocellular Carcinoma2017; : 51 doi: 10.1007/978-3-319-64958-0_4
4
Naofumi Mukaida, Yasunari Nakamoto. Emergence of immunotherapy as a novel way to treat hepatocellular carcinomaWorld Journal of Gastroenterology 2018; 24(17): 1839-1858 doi: 10.3748/wjg.v24.i17.1839
5
Fabian Finkelmeier, Özge Canli, Andrea Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten, Oliver Waidmann. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosisEuropean Journal of Cancer 2016; 59: 152 doi: 10.1016/j.ejca.2016.03.002
6
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes. Immune checkpoint inhibitors for hepatocellular carcinomaHepatic Oncology 2016; 3(3): 201 doi: 10.2217/hep-2016-0004
7
Carolina Boni, Valeria Barili, Greta Acerbi, Marzia Rossi, Andrea Vecchi, Diletta Laccabue, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. HBV Immune-Therapy: From Molecular Mechanisms to Clinical ApplicationsInternational Journal of Molecular Sciences 2019; 20(11): 2754 doi: 10.3390/ijms20112754
8
Colleen S. Curran, Elad Sharon. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinomaSeminars in Oncology 2017; 44(6): 428 doi: 10.1053/j.seminoncol.2017.12.001
9
Mariko Ishibashi, Hiromi Yamaguchi, Yukari Hirotani, Akihisa Sakurada, Toshihide Endo, Masahiko Sugitani, Tadatoshi Takayama, Makoto Makishima, Mariko Esumi. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load liversArchives of Virology 2018; 163(4): 855 doi: 10.1007/s00705-017-3675-8
10
Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng. Soluble PD-L1 and prognosis of patients with hepatocellular carcinomaEuropean Journal of Cancer 2017; 71: 117 doi: 10.1016/j.ejca.2016.09.040
11
Maridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, Kris Thielemans, Hendrik Reynaert. Current status and perspectives of immune-based therapies for hepatocellular carcinomaWorld Journal of Gastroenterology 2016; 22(1): 253-261 doi: 10.3748/wjg.v22.i1.253
12
Tim F. Greten, Firouzeh Korangy. Immunotherapy of Hepatocellular Carcinoma2017; : 121 doi: 10.1007/978-3-319-64958-0_8
13
Scott Balsitis, Volodymyr Gali, Pamela J. Mason, Susan Chaniewski, Steven M. Levine, Michael J. Wichroski, Michael Feulner, Yunling Song, Karen Granaldi, James K. Loy, Chris M. Thompson, Jacob A. Lesniak, Catherine Brockus, Narendra Kishnani, Stephan Menne, Mark I. Cockett, Renuka Iyer, Stephen W. Mason, Daniel J. Tenney, Isabelle Chemin. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infectionPLOS ONE 2018; 13(2): e0190058 doi: 10.1371/journal.pone.0190058
14
Ming-fa Chen, Yong Lin, You-chen Xia, Chan Sun, Xue-mei Feng, Meng-ji Lu, Dong-liang Yang, Jun Wu. Establishment and application of hepatitis B virus persistent replication model in IFNAR−/− mouseJournal of Huazhong University of Science and Technology [Medical Sciences] 2013; 33(3): 392 doi: 10.1007/s11596-013-1130-y
15
Weimin Zhu, Rui Bao, Xiaohua Fan, Tianzhu Tao, Jiali Zhu, Jiafeng Wang, Jinbao Li, Lulong Bo, Xiaoming Deng. PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture ModelMediators of Inflammation 2013; 2013: 1 doi: 10.1155/2013/361501
16
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaHepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
17
Elisabetta Cariani, Gabriele Missale. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applicationsLiver International 2019; 39(9): 1608 doi: 10.1111/liv.14192
18
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinomaWorld Journal of Gastroenterology 2019; 25(20): 2416-2429 doi: 10.3748/wjg.v25.i20.2416
19
Fanzhi Meng, Shoumei Zhen, Bin Song. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunityAPMIS 2017; 125(8): 743 doi: 10.1111/apm.12704
20
Noelle A. Hutchins, Fei Wang, Yvonne Wang, Chun-Shiang Chung, Alfred Ayala. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1Journal of Leukocyte Biology 2013; 94(5): 963 doi: 10.1189/jlb.0113051
21
Xianjing Li, Zhuo Wang, Yulian Zou, Ermei Lu, Jingjing Duan, Hongbao Yang, Qijin Wu, Xiaona Zhao, Yun Wang, Linjun You, Ling He, Tao Xi, Yong Yang. Pretreatment with lipopolysaccharide attenuates diethylnitrosamine-caused liver injury in mice via TLR4-dependent induction of Kupffer cell M2 polarizationImmunologic Research 2015; 62(2): 137 doi: 10.1007/s12026-015-8644-2
22
Sehar Afreen, Said Dermime. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stoneHematology/Oncology and Stem Cell Therapy 2014; 7(1): 1 doi: 10.1016/j.hemonc.2013.09.005
23
Edoardo Giannini, Andrea Aglitti, Mauro Borzio, Martina Gambato, Maria Guarino, Massimo Iavarone, Quirino Lai, Giovanni Levi Sandri, Fabio Melandro, Filomena Morisco, Francesca Ponziani, Maria Rendina, Francesco Russo, Rodolfo Sacco, Mauro Viganò, Alessandro Vitale, Franco Trevisani. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical PracticeCancers 2019; 11(11): 1689 doi: 10.3390/cancers11111689
24
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directionsHepatology 2014; 60(5): 1776 doi: 10.1002/hep.27246
25
Omneya Y. Bassyoni, Heba M. Rashad. Expression of PD-1/PD-L1 and P53 in hepatocellular carcinomaEgyptian Journal of Pathology 2018; 38(1): 131 doi: 10.1097/01.XEJ.0000542236.83764.02
26
Zuzana Macek Jilkova, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Sturm, Patrice N. Marche, Thomas Decaens. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 TreatmentClinical and Translational Gastroenterology 2019; 10(7): e00058 doi: 10.14309/ctg.0000000000000058
27
Stephen A. Locarnini, Michael Roggendorf. Viral Hepatitis2013; : 96 doi: 10.1002/9781118637272.ch7
28
Yaron Ilan. Immune therapy for hepatocellular carcinomaHepatology International 2014; 8(S2): 499 doi: 10.1007/s12072-013-9501-9
29
Yiyi Yan. The Basics of Cancer Immunotherapy2018; : 125 doi: 10.1007/978-3-319-70622-1_8
30
Zhu Li, Na Li, Fang Li, Zhihua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinomaMedicine 2016; 95(52): e5749 doi: 10.1097/MD.0000000000005749
31
Hazel Lote, Catherine Cafferkey, Ian Chau. PD-1 and PD-L1 blockade in gastrointestinal malignanciesCancer Treatment Reviews 2015; 41(10): 893 doi: 10.1016/j.ctrv.2015.09.004
32
Junsik Park, Minsuk Kwon, Eui-Cheol Shin. Immune checkpoint inhibitors for cancer treatmentArchives of Pharmacal Research 2016; 39(11): 1577 doi: 10.1007/s12272-016-0850-5
33
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and ChallengesCancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
34
G Lin, W Zhuang, X H Chen, C Huang, X D Lin, Y J Huang, C Li. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis BAnnals of Oncology 2018; 29(2): 516 doi: 10.1093/annonc/mdx694
35
Oxana V. Makarova-Rusher, José Medina-Echeverz, Austin G. Duffy, Tim F. Greten. The yin and yang of evasion and immune activation in HCCJournal of Hepatology 2015; 62(6): 1420 doi: 10.1016/j.jhep.2015.02.038
36
Zongwen Shuai, Miranda WY Leung, Xiaosong He, Weici Zhang, Guoxiang Yang, Patrick SC Leung, M Eric Gershwin. Adaptive immunity in the liverCellular & Molecular Immunology 2016; 13(3): 354 doi: 10.1038/cmi.2016.4
37
Tim F. Greten, Bruno Sangro. Targets for immunotherapy of liver cancerJournal of Hepatology 2018; 68(1): 157 doi: 10.1016/j.jhep.2017.09.007
38
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura. Potentiality of immunotherapy against hepatocellular carcinomaWorld Journal of Gastroenterology 2015; 21(36): 10314-10326 doi: 10.3748/wjg.v21.i36.10314
39
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizonsEuropean Journal of Cancer 2015; 51(3): 327 doi: 10.1016/j.ejca.2014.12.005
40
Michael A. Nalesnik. Hepatocellular Carcinoma2016; : 305 doi: 10.1007/978-3-319-34214-6_20
41
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular CarcinomaFrontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00015
42
Ken Takahashi, Hiroyuki Marusawa. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal MalignancyCurrent Human Cell Research and Applications 2018; : 93 doi: 10.1007/978-981-10-6469-2_6
43
James J. Harding, Imane El Dika, Ghassan K. Abou-Alfa. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?Cancer 2016; 122(3): 367 doi: 10.1002/cncr.29769
44
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular CarcinomaCancer Research and Treatment 2017; 49(1): 246 doi: 10.4143/crt.2016.066
45
Smitha Menon, Sarah Shin, Grace Dy. Advances in Cancer Immunotherapy in Solid TumorsCancers 2016; 8(12): 106 doi: 10.3390/cancers8120106
46
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapyJournal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0511-2
47
Bruno Sangro, Daniel Palmer, Ignacio Melero. Immunotherapy of hepatocellular carcinomaHepatic Oncology 2014; 1(4): 433 doi: 10.2217/hep.14.16
48
Edward N. Harris, Justin L. Mott. Molecules, Systems and Signaling in Liver Injury2017; : 1 doi: 10.1007/978-3-319-58106-4_1
49
Yingxin Han, Hongmei Li, Yanfang Guan, Jian Huang. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinomaCancer Letters 2016; 379(2): 206 doi: 10.1016/j.canlet.2015.06.022
50
Hao-Wen Sim, Jennifer Knox. Hepatocellular carcinoma in the era of immunotherapyCurrent Problems in Cancer 2018; 42(1): 40 doi: 10.1016/j.currproblcancer.2017.10.007
51
Hui Li, Jun-Quan Xia, Fang-Shi Zhu, Zhao-Hong Xi, Cheng-Yu Pan, Li-Mei Gu, Yao-Zhou Tian. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activationJournal of Cellular Biochemistry 2018; 119(12): 9997 doi: 10.1002/jcb.27329
52
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinomaWorld Journal of Meta-Analysis 2019; 7(3): 80-95 doi: 10.13105/wjma.v7.i3.80
53
Elias A. Said, Iman Al-Reesi, Marwa Al-Riyami, Khalid Al-Naamani, Shadia Al-Sinawi, Mohammed S. Al-Balushi, Crystal Y. Koh, Juma Z. Al-Busaidi, Mohamed A. Idris, Ali A. Al-Jabri, Jean-Pierre Vartanian. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV InfectionPLOS ONE 2016; 11(6): e0158265 doi: 10.1371/journal.pone.0158265
54
Zhi-liang Wang, Guan-zhang Li, Qiang-wei Wang, Zhao-shi Bao, Zheng Wang, Chuan-bao Zhang, Tao Jiang. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factorOncoImmunology 2019; 8(2): e1541535 doi: 10.1080/2162402X.2018.1541535
55
Lina Quan, Xue Chen, Aichun Liu, Yan Zhang, Xiuchen Guo, Shujie Yan, Yue Liu, Luwen Zhang. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In VitroPLOS ONE 2015; 10(9): e0136476 doi: 10.1371/journal.pone.0136476
56
Koji Sawada, Hidemi Hayashi, Shunsuke Nakajima, Takumu Hasebe, Mikihiro Fujiya, Toshikatsu Okumura. Non‐alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitorJournal of Gastroenterology and Hepatology 2019;  doi: 10.1111/jgh.14889
57
Ryan M. Hickey, Laura M. Kulik, Halla Nimeiri, Aparna Kalyan, Sheetal Kircher, Kush Desai, Ahsun Riaz, Robert J. Lewandowski, Riad Salem. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology ProceduresJournal of Vascular and Interventional Radiology 2017; 28(11): 1487 doi: 10.1016/j.jvir.2017.07.018
58
Hao Qiu, Liang Zheng, Weifeng Tang, Pengfei Yin, Feng Cheng, Lixin Wang. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancerClinical Biochemistry 2014; 47(7-8): 612 doi: 10.1016/j.clinbiochem.2013.12.023
59
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapiesExpert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
60
A. J. Robert McGray, Jonathan Bramson. Tumor Immune Microenvironment in Cancer Progression and Cancer TherapyAdvances in Experimental Medicine and Biology 2017; 1036: 213 doi: 10.1007/978-3-319-67577-0_14
61
Daniel L. Suzman, Lorraine Pelosof, Amy Rosenberg, Mark I. Avigan. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agentsLiver International 2018; 38(6): 976 doi: 10.1111/liv.13746
62
Feng Gao, Yang Zhang, Li-Kun Wang, Yong-Li Wei, Jing-Wei Wang, Cheng-Bao Wang, Qiang Li. A Meta-Analysis of the Correlation Between the HLA-DRB1*03 Allele and Chronic Hepatitis B in the Han Chinese PopulationGenetic Testing and Molecular Biomarkers 2015; 19(4): 218 doi: 10.1089/gtmb.2014.0096
63
Rong-Miao Zhou, Yan Li, Na Wang, Xi Huang, Shi-Ru Cao, Bao-En Shan. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinomaCancer Genetics 2016; 209(9): 365 doi: 10.1016/j.cancergen.2016.06.006